VK Gadi, MD, PhD

Articles

Managing Abemaciclib-Associated Toxicities in HR+/HER2- Early Breast Cancer

Komal Jhaveri, MD, FACP;Aditya Bardia, MD, MPH;VK Gadi, MD, PhD;Timothy J. Pluard, MD;Gregory Vidal, MD, PhD

July 11th 2023

VK Gadi, MD, PhD, shares his strategies for managing adverse events related to abemaciclib in the treatment of HR+/HER2- breast cancer.

Recent Data on Adjuvant Therapies in HR+/HER2- Breast Cancer

Komal Jhaveri, MD, FACP;Aditya Bardia, MD, MPH;VK Gadi, MD, PhD;Timothy J. Pluard, MD;Gregory Vidal, MD, PhD

July 11th 2023

Experts on HR+/HER2- breast cancer review data updates on adjuvant therapies from the 2023 ASCO Annual Meeting.

Circulating Tumor DNA as a Prognostic Marker in HR+/HER2- Breast Cancer

Komal Jhaveri, MD, FACP;Aditya Bardia, MD, MPH;VK Gadi, MD, PhD;Timothy J. Pluard, MD;Gregory Vidal, MD, PhD

July 4th 2023

A discussion on the use of circulating tumor DNA (ctDNA) as a prognostic biomarker in HR+/HER2- breast cancer.

Recent Data on Neoadjuvant Therapy in HR+/HER2- Breast Cancer

Komal Jhaveri, MD, FACP;Aditya Bardia, MD, MPH;VK Gadi, MD, PhD;Timothy J. Pluard, MD;Gregory Vidal, MD, PhD

July 4th 2023

The expert panel reviews data updates on neoadjuvant therapy in HR+/HR2- early breast cancer and discusses the role of CDK4/6 inhibition in this setting.

Unmet Needs in Early-Stage HR+/HER2- Breast Cancer

Komal Jhaveri, MD, FACP;Aditya Bardia, MD, MPH;VK Gadi, MD, PhD;Timothy J. Pluard, MD;Gregory Vidal, MD, PhD

June 27th 2023

Experts on HR+/HER2- breast cancer discuss unmet needs in the early-stage setting.

Standard-of-Care Treatment Approaches for HR+/HER2 Early Breast Cancer

Komal Jhaveri, MD, FACP;Aditya Bardia, MD, MPH;VK Gadi, MD, PhD;Timothy J. Pluard, MD;Gregory Vidal, MD, PhD

June 27th 2023

A panel of expert oncologists review standard-of-care treatment approaches for HR+/HER2- early breast cancer and genetic testing practices when utilizing PARP inhibitors.

Dr. Gadi on the Investigation of AMUN-003 in TNBC

VK Gadi, MD, PhD

December 21st 2022

Vijayakrishna Gadi, MD, PhD, discusses the investigation of AMUN-003 in triple-negative breast cancer.

Future Directions in Care for HER2+ Breast Cancer

Andrew D. Seidman, MD;VK Gadi, MD, PhD;Tiffany A. Traina, MD;William J. Gradishar, MD;Stephanie L. Graff, MD, FACP

August 15th 2022

Before closing out their panel on HER2+ breast cancer, expert oncologists share closing thoughts and their excitement for the evolving treatment landscape.

Interpreting Clinical Trial Data in the Setting of HER2-Low Breast Cancer

Andrew D. Seidman, MD;VK Gadi, MD, PhD;Tiffany A. Traina, MD;William J. Gradishar, MD;Stephanie L. Graff, MD, FACP

August 15th 2022

Panelists focus on clinical trial data driving use of novel agents in the setting of HER2-low breast cancer and consider how they might select specific therapies.

Novel Treatment Strategies for HER2-Low Breast Cancer

Andrew D. Seidman, MD;VK Gadi, MD, PhD;Tiffany A. Traina, MD;William J. Gradishar, MD;Stephanie L. Graff, MD, FACP

August 8th 2022

Comprehensive insight on the novel treatment strategies available for patients diagnosed with HER2-low breast cancer.

Establishing the Paradigm of HER2-Low Breast Cancer

Andrew D. Seidman, MD;VK Gadi, MD, PhD;Tiffany A. Traina, MD;William J. Gradishar, MD;Stephanie L. Graff, MD, FACP

August 8th 2022

Expert perspectives on the advent of HER2-low disease and how it has been historically managed since its emergence as a subset of breast cancer.

Ongoing Studies With Novel Agents in HER2+ Metastatic Breast Cancer

Andrew D. Seidman, MD;VK Gadi, MD, PhD;Tiffany A. Traina, MD;William J. Gradishar, MD;Stephanie L. Graff, MD, FACP

August 1st 2022

Before sharing a final review of treatment options for HER2+ metastatic breast cancer, expert oncologists highlight ongoing clinical trials in this setting.

HER2+ mBC: Practical Selection and Sequencing of Therapy

Andrew D. Seidman, MD;VK Gadi, MD, PhD;Tiffany A. Traina, MD;William J. Gradishar, MD;Stephanie L. Graff, MD, FACP

August 1st 2022

Comprehensive discussion on how oncologists may practically select and sequence novel treatment approaches in HER2+ metastatic breast cancer.

Novel Treatment Approaches to Brain Metastases in HER2+ Breast Cancer

Andrew D. Seidman, MD;VK Gadi, MD, PhD;Tiffany A. Traina, MD;William J. Gradishar, MD;Stephanie L. Graff, MD, FACP

July 25th 2022

Focusing on the management of brain metastases in HER2+ metastatic breast cancer, panelists share trial data on tucatinib and trastuzumab deruxtecan.

HER2+ Metastatic Breast Cancer: Safety Data With T-DXd

Andrew D. Seidman, MD;VK Gadi, MD, PhD;Tiffany A. Traina, MD;William J. Gradishar, MD;Stephanie L. Graff, MD, FACP

July 25th 2022

Homing in on trastuzumab deruxtecan, T-DXd, expert panelists review recent safety data in the setting of HER2+ metastatic breast cancer.

Overview of Treatment Options in HER2+ Metastatic Breast Cancer

Andrew D. Seidman, MD;VK Gadi, MD, PhD;Tiffany A. Traina, MD;William J. Gradishar, MD;Stephanie L. Graff, MD, FACP

July 18th 2022

Shared insight on the treatment armamentarium for patients diagnosed with HER2+ metastatic breast cancer.

Escalation or Deescalation of Therapy in Early-Stage HER2+ Breast Cancer

Andrew D. Seidman, MD;VK Gadi, MD, PhD;Tiffany A. Traina, MD;William J. Gradishar, MD;Stephanie L. Graff, MD, FACP

July 18th 2022

Before closing out their discussion on early-stage HER2+ breast cancer, expert oncologists define the value of escalating or deescalating therapy.

Early-Stage HER2+ Breast Cancer: Novel Perioperative Treatment Strategies

Andrew D. Seidman, MD;VK Gadi, MD, PhD;Tiffany A. Traina, MD;William J. Gradishar, MD;Stephanie L. Graff, MD, FACP

July 11th 2022

Subject matter experts in breast oncology discuss ongoing clinical trials in early-stage HER2+ breast cancer that focus on perioperative therapies.

Establishing the Role of Neratinib Therapy in Early-Stage HER2+ Breast Cancer

Andrew D. Seidman, MD;VK Gadi, MD, PhD;Tiffany A. Traina, MD;William J. Gradishar, MD;Stephanie L. Graff, MD, FACP

July 11th 2022

Expert oncologists share their perspectives on when it would be appropriate to consider neratinib therapy in early-stage HER2+ breast cancer.

Updates in the Treatment of HER2+ mBC from ASCO 2022

VK Gadi, MD, PhD

July 8th 2022

A leader in breast medical oncology reflects on key clinical trial updates presented at the 2022 ASCO Annual Meeting, and their implications for clinical practice.

Role of Multidisciplinary Team in the Management of Patients with HER2+ BC and CNS Metastases

VK Gadi, MD, PhD

July 8th 2022

Highlighting the importance of a multidisciplinary approach to care in HER2+ mBC, Vijayakrishna Gadi, MD, PhD, describes the value of effective consultation with neurooncologists and radiation oncologists for CNS metastases.

Early Stage HER2+ Breast Cancer: Optimizing Use of T-DM1

Andrew D. Seidman, MD;VK Gadi, MD, PhD;William J. Gradishar, MD;Tiffany A. Traina, MD;Stephanie L. Graff, MD, FACP

July 4th 2022

A brief discussion on the role of trastuzumab emtansine, T-DM1, in patients with early-stage HER2+ breast cancer.

Subcutaneous HP Therapy in Early-Stage HER2+ Breast Cancer

Andrew D. Seidman, MD;VK Gadi, MD, PhD;Tiffany A. Traina, MD;William J. Gradishar, MD;Stephanie L. Graff, MD, FACP

July 4th 2022

Panelists review clinical data behind subcutaneous HP therapy in early stage HER2+ breast cancer and elucidate the real-world use of this approach.

Selecting and Sequencing Therapy in Patients with HER2+ mBC and CNS Metastases

VK Gadi, MD, PhD

July 1st 2022

An expert oncologist reviews key considerations in selecting and sequencing treatment appropriately in patients with HER2+ breast cancer and CNS metastases, including challenges associated with treating leptomeningeal disease.

Evolving Approaches in the First- and Second-Line Treatment of HER2+ mBC

VK Gadi, MD, PhD

July 1st 2022

Vijayakrishna Gadi, MD, PhD, discusses factors to consider in the first- and second-line management of HER2+ mBC with particular emphasis on treatment selection, safety, and sequencing.

HER2 Dual Blockade in Early Stage HER2+ Breast Cancer

Andrew D. Seidman, MD;VK Gadi, MD, PhD;Tiffany A. Traina, MD;William J. Gradishar, MD;Stephanie L. Graff, MD, FACP

June 27th 2022

Shared insight on the optimal use of HER2 dual-blockade strategies in patients with early stage HER2+ breast cancer.

Early Stage HER2+ Breast Cancer: Overview of Adjuvant Treatment

Andrew D. Seidman, MD;VK Gadi, MD, PhD;Tiffany A. Traina, MD;William J. Gradishar, MD;Stephanie L. Graff, MD, FACP

June 27th 2022

Expert oncologists review adjuvant treatment strategies in early stage HER2+ breast cancer and consider when observation alone would be appropriate.

Evolving Treatment Landscape of HER2+ Metastatic Breast Cancer

VK Gadi, MD, PhD;Charles Geyer, MD, FACP;Nancy Lin, MD;Michelle Melisko, MD

March 10th 2022

Closing out their discussion on novel therapies for HER2+ metastatic breast cancer, experts share excitement for future clinical trials and strategies.